Koers Corbus Pharmaceuticals Holdings, Inc.
Aandelen
CRBP
US21833P3010
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
35,54 USD | -5,83% | -13,57% | +488,41% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 397 mln. 371 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -53 mln. -49,55 mln. | Nettowinst (verlies) 2025 * | -65 mln. -60,77 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-7,25
x | K/w-verhouding 2025 * |
-7,37
x | Werknemers | 19 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,31% |
Recentste transcriptie over Corbus Pharmaceuticals Holdings, Inc.
1 dag | -5,83% | ||
1 week | -13,57% | ||
Lopende maand | -9,43% | ||
1 maand | +1,72% | ||
3 maanden | +386,85% | ||
6 maanden | +513,82% | ||
Lopend jaar | +488,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 01-07-13 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 11-04-14 |
Chief Tech/Sci/R&D Officer | 50 | 28/02 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 01-01-14 |
Avery Catlin
BRD | Director/Board Member | 75 | 01-08-14 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 01-07-13 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 35,54 | -5,83% | 220 976 |
23-04-24 | 37,74 | +0,11% | 500 521 |
22-04-24 | 37,7 | -3,92% | 94 730 |
19-04-24 | 39,24 | +7,42% | 283 601 |
18-04-24 | 36,53 | -1,70% | 128 065 |
uitgestelde koers Nasdaq, 24 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+488,41% | 397 mln. | |
-1,51% | 105 mld. | |
+3,22% | 97,5 mld. | |
+1,86% | 22,19 mld. | |
-16,53% | 21,33 mld. | |
-8,49% | 18,68 mld. | |
-42,33% | 16,6 mld. | |
-20,09% | 14,52 mld. | |
+5,47% | 14,09 mld. | |
+28,85% | 10,99 mld. |